Overview
- Lilly said Monday it will acquire Boston‑based Kelonia for $3.25 billion upfront with milestone payments that could lift the total to $7 billion, with closing expected in the second half of 2026 pending approvals.
- Kelonia’s lead therapy, KLN‑1010, is designed to turn a patient’s T cells into anti‑BCMA CAR‑T cells with a single intravenous infusion, avoiding lab‑based cell engineering and pre‑treatment chemotherapy.
- Early Phase 1 data presented at the ASH 2025 meeting showed rapid, deep responses in a small multiple myeloma cohort, and the FDA cleared an IND in January to expand U.S. trial sites.
- Lilly frames the deal as a push beyond its weight‑loss blockbusters into next‑wave oncology and genetic medicines, following recent buys including Orna Therapeutics and Centessa Pharmaceuticals.
- Lilly executives praised Kelonia’s results as “nothing short of remarkable,” while Crunchbase noted the price ranks among the largest venture‑backed biotech acquisitions in recent years after Kelonia raised about $60 million.